Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
30 hedge funds and large institutions have $138M invested in Clearside Biomedical in 2016 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 5 closing their positions.
300% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 5
161% more capital invested
Capital invested by funds: $52.8M → $138M (+$84.8M)
100% more funds holding
Funds holding: 15 → 30 (+15)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.71M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.76M |
| 4 |
State Street
Boston,
Massachusetts
|
+$462K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$344K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.05M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.05M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$603K |
| 4 |
IHM
Iguana Healthcare Management
New York
|
-$526K |
| 5 |
Millennium Management
New York
|
-$485K |
CLSD Hedge Fund Activity: Q3 2016 in Review
30 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q3 2016, worth a combined $138M — up 161% from $52.8M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new CLSD positions and 5 closed out — a net gain of 15 holders — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $2.71M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.05M sold.
- 30 institutional investors held Clearside Biomedical (CLSD) as of Q3 2016, up from 15 in Q2 2016.
- Funds reported $138M of Clearside Biomedical stock for Q3 2016, up 161% quarter-over-quarter.
- 20 funds opened new Clearside Biomedical positions in Q3 2016 and 5 closed out, a net change of +15 holders.
- The largest Clearside Biomedical buyer in Q3 2016 was Vanguard Group, an estimated $2.71M added.
- The largest Clearside Biomedical seller in Q3 2016 was Alyeska Investment Group, an estimated $1.05M sold.
Based on aggregated 13F filings for Q3 2016.